The diabesity epidemic is steadily increasing every year. Therefore, we are searching for new treatments. The therapeutic potential of oxyntomodulin (OXM) is very promising. Based on evolutionary OXMs, we have identified a developmental OXM candidate known as OXM-001.
Acute administration of OXM-001 resulted in hypophagia, and a numerical greater bodyweight loss, when compared to MEDI0382 (Dual GLP-1/Glucagon receptor agonist) treatment. MEDI0382-treated High-Fat-Diet (HFD), fed female C57BL/6J mice. We examined the effect of repeated administration of OXM-001 in HFD fed female C57BL/6J mice in a 20-day study. Repeated administration every third day of OXM-001 (10, 30 and 100 nmol/kg) significantly reduced body weight in a dose-depended manner. The mean body weight loss was 3.6% (10 nmol/kg, ns), 11% (30 nmol/kg, p <0.0001) and 13.9% (100 nmol/kg, (p <0.0001) compared to Vehicle-treated controls. OXM-001 administration lowered the cumulative food intake dose-dependably, 9.4% (10 nmol/kg, ns), 23.6% (30 nmol/kg, p <0.05) and 32.3% (100 nmol/kg, p <0.05) when compared to Vehicle-treated controls. We also examined the chronic OXM effect on glucose control at day 20 by performing an OGTT. Treatment with OXM significantly (p<0.0001) lowered BG levels (%) in a dose-depended manner compared to Vehicle-treated controls. OXM-001 treatment reduced visceral adipose tissue and liver weight when compared to Vehicle-treated controls.
In summary, these preliminary data indicate that OXM-001 is superior to the current lead MEDI0382. OXM-001 treatment markedly enhanced glucose control. Furthermore, treatment with OXM-001 indicated a tendency toward visceral adipose tissue reduction and improved liver health.
A. Kayed: None. K.V. Andreassen: Employee; Self; Nordic Bioscience. M.A. Karsdal: Employee; Self; Nordic Bioscience. K. Henriksen: Employee; Self; Nordic Bioscience. Employee; Spouse/Partner; Novo Nordisk A/S. Stock/Shareholder; Self; Nordic Bioscience. Other Relationship; Self; Nordic Bioscience.
